OUR MISSION
Restoring Balance to the Immune System
FoxBio Therapeutics is a biotechnology company, founded by a team of experts in Cell and Gene Therapies committed to delivering innovative treatments for patients with severe immune-mediated inflammatory diseases.
Targeted treatment of chronic inflamatory diseases doesn’t just reduce symptoms, it can prevent irreversible organ damage and reduce healthcare utilization. Advances in immunology and enginneering offer a unique opportunity to radically improve outcomes.
The Unmet Need
A Global Health and Economic Burden
Chronic inflammatory diseases are not just a growing health burden: they are a global crisis. Over 80 distinct immune-mediated inflammatory diseases exist, including rheumatoid arthritis, psoriasis, multiple sclerosis, lupus and inflammatory bowel disease (Crohn’s and ulcerative colitis).
Together, they affect over 5–7% of the global population; that’s more than 500 million people worldwide.
These diseases often begin early in life and are lifelong, leading to significant disability and reduced quality of life.
Crohn’s disease
as first indication
In Crohn’s disease, up to 40% of patients fail first-line biologics within one year.
Nearly 30% must undergo surgery, often repeatedly.
Quality of life remains drastically impaired, especially for young adults. Patients urgently need a new approach, one that treats the cause, not just the consequences.
Contact us
